- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer | 14 | Benzinga.com | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.10. | Kairos Pharma meldet positive Zwischenergebnisse in Prostatakrebs-Studie | 11 | Investing.com Deutsch | ||
| 06.10. | Kairos Pharma, LTD. - 8-K, Current Report | 4 | SEC Filings | ||
| 14.09. | Kairos Pharma auf der H.C. Wainwright Konferenz: Strategie gegen Medikamentenresistenz im Fokus | 2 | Investing.com Deutsch | ||
| 14.09. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Kairos Pharma to conduct 1-for-7 reverse stock split | 1 | Investing.com | ||
| 21.08. | Kairos Pharma announces 1-for-7 reverse stock split to maintain NYSE compliance | 2 | Seeking Alpha | ||
| 21.08. | Kairos Pharma kündigt Aktienzusammenlegung im Verhältnis 1 zu 7 an | 1 | Investing.com Deutsch | ||
| 21.08. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Kairos Pharma Announces 1-for-7 Reverse Stock Split | 243 | Business Wire | LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct... ► Artikel lesen | |
| 12.08. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.07. | Kairos Pharma Announces Strategic Collaboration With Bayer To Enhance XOFIGO Activity In Metastatic Prostate Cancer | 34 | pulse2.com | ||
| 22.07. | Bayer, Kairos Pharma Collaborate to Boost Xofigo Effectiveness in Metastatic Prostate Cancer | 48 | Contract Pharma | ||
| 22.07. | Kairos Pharma partners with Bayer on prostate cancer study | 53 | Investing.com | ||
| 22.07. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? | 1 | Benzinga.com | ||
| 15.07. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever | 495 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 15.07. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Kairos Pharma signs term sheet to acquire lung cancer asset | 3 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 11,500 | +1,23 % | Novavax: Was der neue Zahlen-Call jetzt verrät | ||
| INOVIO PHARMACEUTICALS | 0,951 | +8,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,303 | -2,10 % | EILMELDUNG bei InflaRx NV: Rutscht die Aktie jetzt unter die entscheidende Marke? - Handeln Sie noch vor Börsenschluss! | ||
| INTELLIA THERAPEUTICS | 10,160 | -0,78 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer | ||
| EDITAS MEDICINE | 2,170 | +6,90 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,362 | -2,69 % | Alle 4 Monate oder täglich oral: Warum Biogen, Roche und NurExone den Zugang zum Nervensystem unterschiedlich lösen | ||
| IBIO | 0,718 | +2,94 % | iBio, Inc. - 8-K, Current Report | ||
| GERON | 1,082 | +2,85 % | Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia | ||
| IMMUNITYBIO | 8,900 | +0,45 % | ImmunityBio bags elusive label extension for Anktiva | ||
| IMMATICS | 6,395 | +1,67 % | Stifel stuft Immatics mit "Buy" ein - Großes Potenzial in der Melanom-Pipeline | ||
| MYRIAD GENETICS | 3,850 | +3,80 % | Myriad Genetics, Inc.: Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)... ► Artikel lesen | |
| MANNKIND | 2,823 | +4,75 % | MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow' for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | ||
| GINKGO BIOWORKS | 10,305 | -0,24 % | What's Going on With Ginkgo Bioworks Stock on Friday? | ||
| IMMUNIC | 6,228 | +4,22 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 13,020 | +2,36 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating... ► Artikel lesen |
Das Unternehmen KAIROS PHARMA LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -12,17 % bei einem Aktienkurs von 0,664 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.